Progynova, 2 mg tablets 21 pcs

Progynova contains estrogen – estradiol valerate, which is converted in the human body into natural 17β-estradiol. Taking Progynova does not suppress ovulation, and there is virtually no change in the production of hormones in the body itself.

Estradiol replenishes estrogen deficiency in the female body after menopause and provides effective treatment of psycho-emotional and vegetative menopausal symptoms (such as hot flashes, increased sweating, sleep disorders, increased nervous excitability, irritability, palpitations, cardialgia, dizziness, headache, decreased libido, muscle and joint pain); involution of skin and mucous membranes, especially mucous membranes of the genitourinary system (urinary incontinence, dryness and irritation of the vaginal mucosa, painfulness during sexual intercourse).

MWH with an adequate dose of estrogen, such as occurs with Progynova reduces bone resorption and delays or stops bone loss in postmenopause. Long-term use of hormone replacement therapy (HRT) has been shown to reduce the risk of periprosthetic bone fractures in postmenopausal women. The rate of bone mass decline when MHT is withdrawn is comparable to that seen in the immediate postmenopausal period. It has not been shown that using MHT can restore bone mass to premenopausal levels.

MGT also has beneficial effects on the collagen content of the skin, as well as skin density, and can also slow the formation of wrinkles.

MGT lowers total cholesterol, low-density lipoprotein cholesterol (LDL), and raises high-density lipoprotein cholesterol (HDL) and triglycerides. The addition of gestagen can interfere to some extent with the effects of estradiol on metabolism. In general, the metabolic effects of MHT are seen as positive and are thought to be involved in reducing the risk of cardiovascular disease in postmenopausal women.

Women who have not had their uterus removed are advised to take additional gestagen for at least 10 days each cycle when using Progynova. This reduces the risk of endometrial hyperplasia and the associated risk of adenocarcinoma in women in this group.

Indications

Hormone replacement therapy (HRT) for menopausal disorders, involutional skin and genitourinary tract changes, menopausal depression and estrogen deficiency symptoms due to natural menopause or sterilization;

Prevention of postmenopausal osteoporosis.

Composition

1 tablet contains:

The active ingredient:

estradiol valerate2 mg;

Associates:

Lactose monohydrate 46 – 250 mg;

Corn starch 26 – 200 mg;

Povidone 25000 – 3 mg;

talc – 2.4 mg;

magnesium stearate – 0.15 mg;

sucrose crystalline 33 – 540 mg;

povidone 700000 – 0.323 mg;

macrogol 6000 – 3.719 mg;

calcium carbonate precipitated 14 – 572 mg;

talc – 7.104 mg;

glycerol 85% (weight/mass) – 0.205 mg;

titanium dioxide (E171, C.1.77891) – 0.411 mg;

indigo carmine (E132, C.1.73015) – 0.051 mg;

montaglycol wax – 0.075 mg.

How to take, the dosage

Overly, after eating, without chewing and drinking a small amount of liquid, 1 tablet daily for 21 days, then a break of 7 days.

In case of menstruation, Proginova should be taken on the 5th day of menstrual bleeding.

In any other case, immediate treatment recommended by the doctor is possible.

If the uterus is preserved, an additional prescription of another hormone, progesterone, is possible. And a doctor’s recommendation is needed: whether the pills should be taken continuously (without intervals) or intermittently.

The time of day of taking Proginova does not matter. However, if the first pill is taken at a certain time of day, you should stick to that time for all subsequent pills.

Contraindications

Side effects

In rare cases, headache, nausea, abnormal stomach function, breast engorgement, weight changes, uterine bleeding, and chloasma.